SGLT2 inhibitor-naïve T2DM patients were, on average, older than healthy volunteers and had higher BMI, systolic blood pressure, fasting blood glucose, and urinary protein and albumin, but lower eGFR. Here, SLC5A2 is linked to type 2 diabetes mellitus.